Development of a Prototype Clinical Decision Support Tool for a Machine Learning Based Individualized Prediction of Outcomes of Hematopoietic Cell Transplantation for Sickle Cell Disease
Subramaniam R, Kane M, Krishnamurti L. Development of a Prototype Clinical Decision Support Tool for a Machine Learning Based Individualized Prediction of Outcomes of Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2024, 30: s65-s66. DOI: 10.1016/j.jtct.2023.12.104.Peer-Reviewed Original ResearchHematopoietic cell transplantationOutcomes of hematopoietic cell transplantationSickle cell diseasePositive predictive valueDecision support toolMachine-learningClinical decision support toolCell transplantationBalanced accuracyGraft failureSupport toolFold cross validationDecision-making methodPositive outcomesPredictive valueGVHD prophylaxis regimensEvent-free survivalBinary classifierUser inputRelevant clinical parametersReceiver operating characteristic curvePrototype decision support toolTraining datasetOperating characteristics curveTest datasetComparison of Outcomes of Hematopoietic Cell Transplantation (HCT) for Asymptomatic Patients with Sickle Cell Disease (SCD) and That of Propensity Matched Symptomatic Patients Undergoing HCT
Katoch D, Nallagatla V, Liang J, Deng Y, Krishnamurti L. Comparison of Outcomes of Hematopoietic Cell Transplantation (HCT) for Asymptomatic Patients with Sickle Cell Disease (SCD) and That of Propensity Matched Symptomatic Patients Undergoing HCT. Transplantation And Cellular Therapy 2024, 30: s65. DOI: 10.1016/j.jtct.2023.12.103.Peer-Reviewed Original ResearchHematopoietic cell transplantationOutcomes of hematopoietic cell transplantationSickle cell diseaseSymptomatic SCD patientsAsymptomatic patientsDonor typeSymptomatic patientsPost-HCTSCD patientsHematopoietic cell transplantation comorbidity indexPost-transplant lymphoproliferative disorderMedian follow-up periodComplication of sickle cell diseaseIncidence of aGVHDReduced intensity conditioningSickle cell disease patientsFollow-up periodPropensity-matched modelStandardized mean differenceSecondary malignanciesLymphoproliferative disordersCell transplantationGraft survivalPatient ageAssociated with group classification